You Position: Home > Paper
B-lymphocyte-targeted therapy for systemic lupus erythematosus
( views:217, downloads:12 )
- Author:
- No author available
- Journal Title:
- INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.1673-4173.2009.02.011
- Key Word:
- 红斑狼疮,系统性;B淋巴细胞;治疗;Lupus erythematosus,systemic;B-lymphocyte;Therapy
Abstract： Treatment of SLE is versatile.B-lymphocyte-targeted therapy is a new clinical approach which has not been generally applied in China.International studies have proved it to be highly effective,safe and tolerable.So.it shows a fine application prospect and is expected to offer a new treatment approach to patients with SLE,especially to those resistant to conventional therapy and those suffering from serious adverse side effects.The true efficacy and long-term side effects of this approach remain to be further evaluated via large-scale trials and long-term follow-up.
- [1].LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study[J].2003,48(2).
- [2]Maria Dall'Era,Eliza Chakravarty,Daniel Wallace,etc.Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial[J].2007,56(12).
- [3]Carugati A,Savill JS,Walport MJ,etc.A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo.[J].2000,192(3).
- [4]Maria J. Leandro,Jonathan C. Edwards,Geraldine Cambridge,etc.An open study of B lymphocyte depletion in systemic lupus erythematosus[J].2002,46(10).
- [5]R S, Scott,E J, McMahon,S M, Pop,etc.Phagocytosis and clearance of apoptotic cells is mediated by MER.[J].2001,411(6834).
- [6]Thomas Dörner,Joerg Kaufmann,William A Wegener,etc.Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus[J].2006,8(3).
- [7]Jennifer H. Anolik,Jennifer Barnard,Amedeo Cappione,etc.Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus[J].2004,50(11).
- [8]Sabahi R,Anolik JH.B-cell-targeted therapy for systemic lupus erythematosus.[J].2006,66(15).
- [9]Nakashima H,Kimoto Y,Otsuka J,etc.A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.[J].2008,47(6).
- [10]Carter RH.B cells in health and disease.[J].2006,81(3).
- [11]Jennifer H, Anolik,Debbie, Campbell,Raymond E, Felgar,etc.The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.[J].2003,48.
- [12]Isenberg DA,Ehrenstein MR,Leandro MJ,etc.B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.[J].2005,44(12).